» Articles » PMID: 15730926

Hepatitis C Virus Genotypes, HLA-DRB Alleles and Their Response to Interferon-alpha and Ribavirin in Patients with Chronic Hepatitis C

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2005 Feb 26
PMID 15730926
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis C virus (HCV) is a worldwide common disease. Some predictive factors influencing the response to interferon alpha (IFN-alpha) therapy have been identified, but the conclusions differ in various counties and areas. The aim of this study was to study the associations between HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin in Chinese patients with chronic hepatitis C in Northeast China.

Methods: HCV genotypes of 113 patients with HCV were investigated. Gene chips were used to analyze the frequency of HLA-DRB in 25 of these patients and their response to IFN-alpha and ribavirin. The associations of HCV genotypes, HLA-DRB alleles and their response to IFN-alpha and ribavirin were also studied.

Results: The response rates differed in several types of HCV, with HCV 2b being the highest (57.78%), HCV 1a and 2a lower (46.15% and 47.62%) and HCV 1b the lowest (11.76%). The response rates to IFN-alpha and ribavirin in patients with DRB1*07 were higher than those with DRB1*04. Sex, HCV type and HLA-DRB were all related to the response. Most female patients with HCV 2b and HLA-DRB1*07 presented complete response, whereas male patients with HCV 1b and HLA-DRB1*04 usually demonstrated no response. DRB1*07 allele and HCV 2b were the factors closely related to the response.

Conclusions: The response rate of HCV 1b may be the lowest even IFN-alpha and ribavirin are combined in treatment. Not only virus but also the host plays an important role in anti-virus therapy. Thus, it is necessary to adjust the host's immune status to accelerate the clearance of HCV.

Citing Articles

Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Shaker O, Bassiony H, Raziky M, El-Kamary S, Esmat G, El-Ghor A Mediators Inflamm. 2013; 2013:392746.

PMID: 23576852 PMC: 3612450. DOI: 10.1155/2013/392746.


Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Ford N, Kirby C, Singh K, Mills E, Cooke G, Kamarulzaman A Bull World Health Organ. 2012; 90(7):540-50.

PMID: 22807600 PMC: 3397704. DOI: 10.2471/BLT.11.097147.


Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Tavis J, Donlin M, Aurora R, Fan X, Di Bisceglie A Genome Med. 2011; 3(2):8.

PMID: 21345258 PMC: 3092093. DOI: 10.1186/gm222.


Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0.

Verbeeck J, Stanley M, Shieh J, Celis L, Huyck E, Wollants E J Clin Microbiol. 2008; 46(6):1901-6.

PMID: 18400913 PMC: 2446848. DOI: 10.1128/JCM.02390-07.


A comparative review of HLA associations with hepatitis B and C viral infections across global populations.

Singh R, Kaul R, Kaul A, Khan K World J Gastroenterol. 2007; 13(12):1770-87.

PMID: 17465466 PMC: 4149952. DOI: 10.3748/wjg.v13.i12.1770.